Impact of an exercise program on acylcarnitines in obesity: A prospective controlled study

Journal of the International Society of Sports Nutrition

Volumn 9, Issue , 2012, Pages

  Rodríguez Gutiérrez, René ^a   Lavalle González, Fernando J ^a   Martínez Garza, Laura E ^b   Landeros Olvera, Erick ^c   López Alvarenga, Juan C ^d   Torres Sepúlveda, Maria R ^b   González González, Jose G ^a   Mancillas Adame, Leonardo G ^a   Salazar Gonzalez, Bertha ^e   Villarreal Pérez, Jesus Z ^a  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^b Centro Regional de Alergia   (Mexico)

^c BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^d HOSPITAL GENERAL DE MÉXICO   (Mexico)

^e UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

Aerobic exercise; Beta oxidation; Diabetes mellitus; Lipotoxicity; Obesity; Overweight

Indexed keywords

EID: 84865534922     PISSN: None     EISSN: 15502783     Source Type: Journal    
DOI: 10.1186/1550-2783-9-22     Document Type: Article

References (43)

1. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer- and service-specific estimates. Health Aff (Millwood) 2009, 28:822-831.
2. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003, 26:917-932.
3. World Health Organization World Health Organization Consultation on Obesity 2000, WHO, Geneva, World Health Organization.
4. Boyle J, Honeycutt A, Narayan K, Hoerger T, Geiss L, Chen H, Thompson T. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001, 24:1936-1940. 10.2337/diacare.24.11.1936, 11679460.
5. Mokdad A, Bowman B, Ford E, Vinicor F, Marks J, Koplan J. The continuing epidemics of obesity and diabetes in the United States. J Am Med Assoc 2001, 286:1195-1200.
6. Dommarco JR, Cuevas Nasu L, Shamah Levy T, Villalpando Hernández S, Avila Arcos MA, Jiménez Aguilar A. Nutrición. In Encuesta Nacionalde Saludy Nutrición 2006, Instituto Nacional de Salud Pública, Cuernavaca, Mexico.
7. Villalpando Hernandez S, Cruz V, Rojas R, Shamah Levy T, Ávila MA, Berenice Gaona B, Rebollar Hernández L. Prevalence and distribution of type 2 diabetes mellitus in Mexican adult population. A probabilistic survey. Salud Pública de México 2010, 52:19-26.
8. DeFronzo RA. Lilly Lecture: The triumvirate: cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988, 37:667-687.
9. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607. 10.2337/diabetes.37.12.1595, 3056758.
10. Abdul-Ghani M, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 2008, 14:782-790.
11. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β-cell dysfunction. Eur J Clin Invest 2002, 32(Suppl 3):14-23.
12. DeFronzo RA. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 Diabetes Mellitus. Diabetes 2009, 58:773-795. 10.2337/db09-9028, 2661582, 19336687.
13. Matsuda M, DeFronzo RA, Glass L, Consoli A, Giordano M, Bressler P, Del Prato S. Glucagon dose response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. Metabolism 2002, 51:1111-1119. 10.1053/meta.2002.34700, 12200754.
14. Matsuda M, Liu Y, Mahankali S, Pu Y, Mahankali A, Wang J, DeFronzo RA, Fox PT, Gao JH. Altered hypothalamic function in response to glucose ingestion in obese humans. Diabetes 1999, 48:1801-1806. 10.2337/diabetes.48.9.1801, 10480611.
15. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987, 64:106-110. 10.1210/jcem-64-1-106, 3536980.
16. Unger RH. Lipotoxic diseases. Annu Rev Med 2002, 53:319-336. 10.1146/annurev.med.53.082901.104057, 11818477.
17. Longo N, San Filippo CA, Pasquali M. Disorders of carnitine trasport and carnitine cycle. Am J Med Genet C Semin Med Genet 2006, 142:77-85.
18. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1:785-789.
19. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002, 51:2944-2950. 10.2337/diabetes.51.10.2944, 12351431.
20. Koves TR, Ussher JR, Noland RC, Sientz D, Mosedale M, Ilkayeva O, Bain J, Stevens R, Dyck JR, Newgard CB, Lopaschuk GD, Muoio DM. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 2008, 7:45-56. 10.1016/j.cmet.2007.10.013, 18177724.
21. McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 1997, 244:1-14. 10.1111/j.1432-1033.1997.00001.x, 9063439.
22. Mihalik SJ, Goodpaster BH, Kelley DE, Chace DH, Vockley J, Toledo FG, Delany JP. Levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring) 2010, 18:1695-1700.
23. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007, 292:871-883.
24. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferranini E, Cusi K, Mandarino L, DeFronzo RA. Improved glycemic control and enhanced insulin sensitivity in liver and muscle in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001, 24:710-719. 10.2337/diacare.24.4.710, 11315836.
25. Hiatt WR, Regensteiner JG, Wolfel EE, Ruff L, Brass EP. Carnitine and acylcarnitine metabolism during exercise in Humans. J Clin Invest 1989, 84:1167-1173. 10.1172/JCI114281, 329774, 2794054.
26. American College of Sports Medicine ACSM's Guidelines for exercise testing and prescription 2010, Lippinkott Williams & Wilkins, New York, 8, American College of Sports Medicine.
27. Noble BJ, Borg GA, Jacobs I, Ceci R, Kaiser P. A category-ratio perceived exertion scale: relationship to blood and muscle lactates and heart rate. Med Sci Sports Exerc 1983, 5:523-528.
28. National Institutes of Health Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998, 2(Suppl 6):461-462. National Institutes of Health.
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419. 10.1007/BF00280883, 3899825.
30. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 2002, 25:1177-1184. 10.2337/diacare.25.7.1177, 12087016.
31. Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, Minkler PE, Hwang DH, Newman JW, Garvey WT. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid β-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr 2009, 139:1073-1081. 10.3945/jn.108.103754, 2714383, 19369366.
32. Kelley DE. Skeletal muscle fat oxidation: timing and flexibility are everything. J Clin Invest 2005, 115:1699-1702. 10.1172/JCI25758, 1159159, 16007246.
33. Kelley DE, Goodpaster BH, Wing RR, Simoneau JA. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity and weight loss. Am J Physiol 1999, 277:1130-1141.
34. Goodpaster BH, Katsiaras A, Kelley DE. Enhanced fat oxidation through physical activity is associated with improvements in insulin sensitivity in obesity. Diabetes 2003, 52:2191-2197. 10.2337/diabetes.52.9.2191, 12941756.
35. Chitwood LF, Brown SP, Lundy MJ, Dupper MA. Metabolic propensity toward obesity in black vs white females: responses during rest, exercise and recovery. Int J Obes Relat Metab Disord 1996, 20:455-462.
36. Franck N, Gummesson A, Jernas M, Glad C, Svensson PA, Guillot G, Rudemo M, Nystörm FH, Carlsson LM, Olsson B. Identification of adipocyte genes regulated by caloric intake. J Clin Endocrinol Metab 2011, 96:413-418.
37. Kraemer RR, Chu H, Castracane VD. Leptin and exercise. Exp Biol Med 2002, 227:701-708.
38. Kriketos AD, Gan SK, Poynten AM, Furler SM, Chisholm DJ, Campbell MB. Exercise increases adiponectin levels and insulin sensitivity in humans. Diabetes Care 2004, 27:629-630. 10.2337/diacare.27.2.629, 14747265.
39. Ross R, Dagnone D, Jones PJH, Smith H, Paddags A, Hudson R, Janssen I. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. Ann Intern Med 2000, 133:92-103.
40. Brodan V, Kuhn E, Pechar J, Tomkovfi D. Changes in free amino acids in plasma of healthy subjects induced by physical exercise. Europ J appl Physiol 1976, 35:69-77.
41. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Hagg AM, Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy WS, Eisenson H, Musante G, Surwit RS, Millington DS, Butler MD, Svetkey LP. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009, 9:311-326. 10.1016/j.cmet.2009.02.002, 19356713.
42. He J, Bret H, Goodpaster BH, Kelley DE. Effects of weight loss and physical activity on muscle lipid content and droplet size. Obes Res 2004, 12:761-769. 10.1038/oby.2004.92, 15166296.
43. Toledo GS, Menshikova EV, Ritov VB, Azuma K, Radikova Z, DeLany J, Kelley DE. Effects of physical activity and weight loss on skeletal muscle mitochondria and relationship with glucose control in type 2 diabetes. Diabetes 2007, 56:2142-2147. 10.2337/db07-0141, 17536063.